Novartis isn't making deals in China just for the sake of buying there. That's the word from CEO Vas Narasimhan, who told reporters on a second-quarter earnings call that the Swiss pharma is “agnostic” to …
Source: Endpoints News
You may also like
Nouscom to present re‑treatment data in Lynch...
ViiV Healthcare to unveil new HIV treatment data at...
Almirall’s paediatric registration of Ebglyss for...
The Bloc appoints Jon Chapman as European Executive...
UCSD, IGI Partnership Expands CRISPR Innovation Across...
10x Clinical Expansion Advances with CLIA Lab Plans...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.